57342-22-0

Basic information

• Product Name: 2-BROMO-1-(4-BromoPHENYL)-1-ETHANONE OXIME
• Synonyms: 2-BROMO-1-(4-BromoPHENYL)-1-ETHANONE OXIME
• CAS NO: 57342-22-0
• Molecular Formula: C₈H₇Br₂NO
• Molecular Weight: 293
• Mol File: 57342-22-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BROMO-1-(4-BromoPHENYL)-1-ETHANONE OXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(4-BromoPHENYL)-1-ETHANONE OXIME(57342-22-0)
• EPA Substance Registry System: 2-BROMO-1-(4-BromoPHENYL)-1-ETHANONE OXIME(57342-22-0)

Safety Data

• Hazardous Substances Data: 57342-22-0(Hazardous Substances Data)

Upstream product

• 99-73-0 para-bromophenacyl bromide 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 17631-15-1 [2-(4-bromo-phenyl)-2-hydroxyimino-ethyl]-tributyl-phosphonium; bromide 
• 63996-33-8 3-(4-bromo-phenyl)-4,4a,5,7a-tetrahydro-cyclopenta[e][1,2]oxazine 
• 26964-97-6 5.5-Dimethyl-3-p-bromphenyl-6-hydroxy-5.6-dihydro-1.2.4H-oxazin 
• 17492-59-0 (3-(4-bromophenyl)-4,5-dihydroisoxazol-5-yl)(phenyl)methanone 
• 1236132-64-1 Te-4-bromoacetophenone oxime benzenecarbotelluroate 
• 17631-19-5 3-(4-bromo-phenyl)-5,5,5-triphenyl-4,5-dihydro-5λ⁵-[1,2,5]oxazaphosphole 
• 17631-24-2 3-(4-bromo-phenyl)-5,5,5-tributyl-4,5-dihydro-5λ⁵-[1,2,5]oxazaphosphole 
• 79379-58-1 2-(p-bromophenyl)-4,5,6,7-tetrahydroindole 
• 21262-87-3 3-(4-bromophenyl)-5-methyl-1,2-oxazole 
• 93752-19-3 6H-2-isopropylidene-1,3,4-dithiazine 
• 99-73-0 para-bromophenacyl bromide 

Relevant articles and documents

α-Nitrosostyrenes as Three-Atom Units for the (3+1) Cyclization Reaction: Facile Access to 2,3-Dihydrodiazete N-Oxides and Their Diversified Synthetic Conversions

An unprecedented (3+1) cyclization of α-nitrosostyrenes, generated in situ from α-bromooximes, and N-tosyloxycarbamates was developed, which enables the synthesis of a range of structurally unique and hitherto unexplored 2,3-dihydrodiazete N-oxides in mod

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: Clues for specific design of new compounds

Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, being one of the inhibitors on clinical trials for different tauopathies. Following our hypothesis based on the enhanced reactivity of residue Cys199 in the binding site of GSK-3, we examine here the suitability of phenylhalomethylketones as irreversible inhibitors. Our data confirm that the halomethylketone unit is essential for the inhibitory activity. Moreover, addition of the halomethylketone moiety to reversible inhibitors turned them into irreversible inhibitors with IC50 values in the nanomolar range. Overall, the results point out that these compounds might be useful pharmacological tools to explore physiological and pathological processes related to signaling pathways regulated by GSK-3 opening new avenues for the discovery of novel GSK-3 inhibitors.